Poxel

Developer of therapeutic solutions for the treatment of Type 2 diabetes

placeLyon, Auvergne Rhone Alpes, France calendar_todayFounded 2009 groups37 employees language poxelpharma.com

Innovation

31 patent families (21 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 995 times.

YearFilings
201512
201611
20178
20187
20195
20207
202113
20225
20236
20244
20254
20262

Investor mix

9 investors on record; lead investors include Edmond de Rothschild; 1 has since exited.

Investor typeCountShare
Private equity444%
Bank & private debt333%
Other / undisclosed222%
Coming soon